The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs
Abstract
Ruthenium anticancer drugs have attracted an increasing interest in the last 20 years and two of them have entered clinical trials. Compared to platinum drugs, the complexes based on ruthenium are often identified as less toxic and capable of overcoming the resistance induced by platinum drugs in cancer cells. These activities were attributed to the transportation to tumour cells by transferrin and to the selective activation to more reactive species by the reducing environment of solid tumours as compared to healthy tissues. Ruthenium anticancer drugs have been almost always designed to mimic platinum drugs, particularly for targeting DNA. Indeed, none of the above properties has never been clearly demonstrated even for the ruthenium drugs that entered clinical trials. The suggestion for the future is to change the perspective when designing new chemical entities, abandoning the philosophy that guided the actual panel of ruthenium drugs and to look further into the fine mechanism by which the most relevant ruthenium complexes available kill the target tumour cells, then focusing on targets selective of tumour cells and responsible for cell growth and malignancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Why Do Cancers Have High Aerobic Glycolysis?
Gatenby, R. A., & Gillies, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1478 · Cited by 4,784
Hartinger, C. G., Zorbas-Seifried, S., Jakupec, M. A., Kynast, B., Zorbas, H., & Keppler, B. K. (2006) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2006.02.013 · Cited by 956
Antitumour metal compounds: more than theme and variations
Jakupec, M. A., Galanski, M. S., Arion, V. B., Hartinger, C. G., & Keppler, B. K. (2008) · Dalton Transactions · doi:10.1039/b712656p · Cited by 850
Rademaker-Lakhai, J. M., van den Bongard, D., Pluim, D., Beijnen, J. H., & Schellens, J. H. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0746 · Cited by 833
In Vitro and in Vivo Evaluation of Ruthenium(II)−Arene PTA Complexes
Scolaro, C., Bergamo, A., Brescacín, L., Delfino, R., Cocchietto, M., Laurenczy, G., Geldbach, T. J., Sava, G., & Dyson, P. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050015d · Cited by 784
Self-citationRuthenium metallopharmaceuticals
Clarke, M. J. (2003) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00312-0 · Cited by 687
Aird, R. E., Cummings, J., Ritchie, A. A., Muir, M., Morris, R. E., Chen, H., Sadler, P. J., & Jodrell, D. I. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600290 · Cited by 582
Ruthenium Complexes as Anticancer Agents
Kostova, I. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706776360941 · Cited by 566
Allardyce, C. S., Dyson, P. J., Ellis, D. J., & Heath, S. L. (2001) · Chemical Communications · doi:10.1039/b104021a · Cited by 495
Ruthenium-based chemotherapeutics: are they ready for prime time?
Antonarakis, E. S., & Emadi, A. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1293-1 · Cited by 489
Targeting proteins with metal complexes
Meggers, E. (2009) · Chemical Communications · doi:10.1039/b813568a · Cited by 450
EGFR Signaling and Drug Discovery
Lurje, G., & Lenz, H.-J. (2009) · Oncology · doi:10.1159/000279388 · Cited by 442
DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity
Brabec, V., & Nováková, O. (2006) · Drug Resistance Updates · doi:10.1016/j.drup.2006.05.002 · Cited by 384
Ruthenium complexes can target determinants of tumour malignancy
Bergamo, A., & Sava, G. (2007) · Dalton Transactions · doi:10.1039/b617769g · Cited by 291
Self-citationChatterjee, S., Kundu, S., Bhattacharyya, A., Hartinger, C. G., & Dyson, P. J. (2008) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-008-0400-9 · Cited by 258
DNA Modifications by antitumor platinum and ruthenium compounds: Their recognition and repair
(2002) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(02)71040-4 · Cited by 230
Smalley, K. S. M., Contractor, R., Haass, N. K., Kulp, A. N., Atilla-Gokcumen, G. E., Williams, D. S., Bregman, H., Flaherty, K. T., Soengas, M. S., Meggers, E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1538 · Cited by 230
Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue
Choy, H., Park, C., & Yao, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2176 · Cited by 217
Meng, X., Leyva, M. L., Jenny, M., Gross, I., Benosman, S., Fricker, B., Harlepp, S., Hébraud, P., Boos, A., Wlosik, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4408 · Cited by 208
Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound
Bergamo (1992) · International Journal of Oncology · doi:10.3892/ijo_00000119 · Cited by 202
Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells
Kapitza, S., Pongratz, M., Jakupec, M. A., Heffeter, P., Berger, W., Lackinger, L., Keppler, B. K., & Marian, B. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0617-0 · Cited by 200
Targeting anoikis resistance in prostate cancer metastasis
Sakamoto, S., & Kyprianou, N. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2010.02.001 · Cited by 180
Targeted manipulation of apoptosis in cancer treatment
Call, J. A., Eckhardt, S. G., & Camidge, D. R. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70209-2 · Cited by 165
Jakupec, M. A., Reisner, E., Eichinger, A., Pongratz, M., Arion, V. B., Galanski, M. S., Hartinger, C. G., & Keppler, B. K. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0490742 · Cited by 164
Bergamo, A., Gagliardi, R., Scarcia, V., Furlani, A., Alessio, E., Mestroni, G., & Sava, G. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38169-8 · Cited by 160
Self-citationInfluence of Hydrogen-Bonding Substituents on the Cytotoxicity of RAPTA Compounds
Scolaro, C., Geldbach, T. J., Rochat, S., Dorcier, A., Gossens, C., Bergamo, A., Cocchietto, M., Tavernelli, I., Sava, G., Röthlisberger, U., et al. (2005) · Organometallics · doi:10.1021/om0508841 · Cited by 157
Self-citationGaiddon, C., Jeannequin, P., Bischoff, P., Pfeffer, M., Sirlin, C., & Loeffler, J. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089342 · Cited by 142
Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A
Vacca, A., Bruno, M., Boccarelli, A., Coluccia, M., Ribatti, D., Bergamo, A., Garbisa, S., Sartor, L., & Sava, G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600176 · Cited by 140
Self-citationZorzet, S., Bergamo, A., Cocchietto, M., Sorc, A., Gava, B., Alessio, E., Iengo, E., & Sava, G. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38990-6 · Cited by 120
Self-citationKapitza, S. B., Jakupec, M. A., Uhl, M., Keppler, B. K., & Marian, B. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.01.002 · Cited by 119
Sava, G., Frausin, F., Cocchietto, M., Vita, F., Podda, E., Spessotto, P., Furlani, A., Scarcia, V., & Zabucchi, G. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.034 · Cited by 91
Self-citationSimilar Biological Activities of Two Isostructural Ruthenium and Osmium Complexes
Maksimoska, J., Williams, D. S., Atilla‐Gokcumen, G. E., Smalley, K. S. M., Carroll, P. J., Webster, R. D., Filippakopoulos, P., Knapp, S., Herlyn, M., & Meggers, E. (2008) · Chemistry - A European Journal · doi:10.1002/chem.200800294 · Cited by 89
Hayward, R. L., Schornagel, Q. C., Tente, R., Macpherson, J. S., Aird, R. E., Guichard, S. M., Habtemariam, A., Sadler, P. J., & Jodrell, D. I. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0932-9 · Cited by 79
Musgrove, E. A., Rugg, C. A., Taylor, I. W., & Hedley, D. W. (1984) · Journal of Cellular Physiology · doi:10.1002/jcp.1041180103 · Cited by 60
Amin, A., & Buratovich, M. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709790361566 · Cited by 47
Forcing Cancer Cells to Commit Suicide
Vangestel, C., de Wiele, C. V., Mees, G., & Peeters, M. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2008.0598 · Cited by 37
Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells
Lieber, J., Kirchner, B., Eicher, C., Warmann, S. W., Seitz, G., Fuchs, J., & Armeanu–Ebinger, S. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22740 · Cited by 35
Treatment of advanced non-small-cell lung cancer in the elderly
Gridelli, C., Maione, P., Rossi, A., Ferrara, M. L., Castaldo, V., Palazzolo, G., & Mazzeo, N. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.08.006 · Cited by 29
Ficorella (2010) · Oncology Reports · doi:10.3892/or_00000805 · Cited by 24
Modulation of cell sensitivity to antitumor agents by targeting survival pathways
Perego, P., Cossa, G., Zuco, V., & Zunino, F. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.07.030 · Cited by 21
Novel ways to sensitise gastrointestinal cancer to apoptosis
Schulze‐Bergkamen, H., Weinmann, A., Moehler, M. H., Siebler, J., & Galle, P. R. (2009) · Gut · doi:10.1136/gut.2008.164350 · Cited by 15
Cited by
Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs
Liu, W., & Gust, R. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35314h · Cited by 762
Stimuli-Responsive Therapeutic Metallodrugs
Wang, X., Wang, X., Jin, S., Muhammad, N., & Guo, Z. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00209 · Cited by 649
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Aquaporins: important but elusive drug targets
Verkman, A. S., Anderson, M. O., & Papadopoulos, M. C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4226 · Cited by 586
N-Heterocyclic carbene metal complexes in medicinal chemistry
Oehninger, L., Rubbiani, R., & Ott, I. (2013) · Dalton Trans. · doi:10.1039/c2dt32617e · Cited by 560
Metadata
- Authors
- Bergamo, A., & Sava, G.
- Venue
- Dalton Transactions
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2011
- Volume
- 40
- Issue
- 31
- Pages
- 7817
- ISSN
- 1477-9226 (ISSN-L)
- 1477-9234
- OpenAlex
- W2034947652
- Cited by
- 440
- References
- 41
- FWCI
- 15.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.